DiaMedica Therapeutics (NASDAQ:DMAC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Several other brokerages have also recently commented on DMAC. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.00.

DiaMedica Therapeutics Stock Up 0.2%

Shares of DMAC stock opened at $8.74 on Friday. DiaMedica Therapeutics has a 12-month low of $5.24 and a 12-month high of $10.42. The firm has a fifty day moving average of $7.39 and a 200-day moving average of $7.11. The company has a market capitalization of $471.35 million, a price-to-earnings ratio of -12.14 and a beta of 0.92.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. On average, equities analysts expect that DiaMedica Therapeutics will post -0.84 EPS for the current year.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several large investors have recently modified their holdings of DMAC. Squarepoint Ops LLC bought a new stake in shares of DiaMedica Therapeutics during the 2nd quarter worth about $1,023,000. AWM Investment Company Inc. bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at about $253,000. Bank of New York Mellon Corp bought a new position in DiaMedica Therapeutics in the 2nd quarter valued at about $829,000. Bank of America Corp DE raised its holdings in DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after acquiring an additional 16,446 shares during the period. Finally, Renaissance Technologies LLC bought a new position in DiaMedica Therapeutics in the 1st quarter valued at about $356,000. 10.12% of the stock is owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company’s research is centered on therapies intended to address conditions with limited treatment options.

DiaMedica’s lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease.